scholarly journals In Vitro Activities of DA-7867, a Novel Oxazolidinone, against Recent Clinical Isolates of Aerobic and Anaerobic Bacteria

2004 ◽  
Vol 48 (5) ◽  
pp. 1918-1918
Author(s):  
Dongeun Yong ◽  
Jong Hwa Yum ◽  
Kyungwon Lee ◽  
Yunsop Chong ◽  
Sung Hak Choi ◽  
...  
Keyword(s):  
Anaerobic Bacteria ◽  
Clinical Isolates ◽  
Aerobic And Anaerobic

scholarly journals Comparative In Vitro Activities of Torezolid (DA-7157) against Clinical Isolates of Aerobic and Anaerobic Bacteria in South Korea

2010 ◽  
Vol 54 (12) ◽  
pp. 5381-5386 ◽  
Author(s):  
Jong Hwa Yum ◽  
Sung Hak Choi ◽  
Dongeun Yong ◽  
Yunsop Chong ◽  
Weon Bin Im ◽  
...  
Keyword(s):  
South Korea ◽  
Antimicrobial Agents ◽  
Anaerobic Bacteria ◽  
Clinical Isolates ◽  
Bacterial Isolates ◽  
First Line ◽  
Gram Positive ◽  
The World ◽  
Aerobic And Anaerobic

ABSTRACT Resistance of Gram-positive pathogens to first-line antimicrobial agents has been increasing in many parts of the world. We compared the in vitro activities of torezolid with those of other antimicrobial agents, including linezolid, against clinical isolates of major aerobic and anaerobic bacteria. Torezolid had an MIC90 of ≤0.5 μg/ml for the Gram-positive bacterial isolates tested and was more potent than either linezolid or vancomycin.

Multilaboratory evaluation of the in vitro activity of 13 β-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria

1993 ◽  
Vol 16 (3) ◽  
pp. 191-203 ◽  
Author(s):  
Patrick R. Murray ◽  
Ronald N. Jones ◽  
Stephen D. Allen ◽  
Meredith E. Erwin ◽  
Peter C. Fuchs ◽  
...  
Keyword(s):  
Anaerobic Bacteria ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Aerobic And Anaerobic

scholarly journals In Vitro Activities of DA-7867, a Novel Oxazolidinone, against Recent Clinical Isolates of Aerobic and Anaerobic Bacteria

2004 ◽  
Vol 48 (1) ◽  
pp. 352-357 ◽  
Author(s):  
Dongeun Yong ◽  
Jong Hwa Yum ◽  
Kyungwon Lee ◽  
Yunsop Chong ◽  
Sung Hak Choi ◽  
...  
Keyword(s):  
Anaerobic Bacteria ◽  
Clinical Isolates ◽  
Bacterial Strains ◽  
Gram Positive ◽  
Aerobic And Anaerobic

ABSTRACT In vitro activities of DA-7867, a novel oxazolidinone, were compared to those of linezolid and commonly used antimicrobials. DA-7867 had the lowest MIC for 90% of the aerobic gram-positive bacterial strains tested, ≤0.25 μg/ml, and it was more potent than linezolid.

scholarly journals In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9-t-Butylglycylamido Derivative of Minocycline (GAR-936)

1999 ◽  
Vol 43 (4) ◽  
pp. 738-744 ◽  
Author(s):  
P. J. Petersen ◽  
N. V. Jacobus ◽  
W. J. Weiss ◽  
P. E. Sum ◽  
R. T. Testa
Keyword(s):  
Anaerobic Bacteria ◽  
Tetracycline Resistance ◽  
Protective Effects ◽  
Gram Negative ◽  
E Coli ◽  
Resistance Determinants ◽  
Aerobic And Anaerobic ◽  
Ribosomal Protection

ABSTRACT The 9-t-butylglycylamido derivative of minocycline (TBG-MINO) is a recently synthesized member of a novel group of antibiotics, the glycylcyclines. This new derivative, like the first glycylcyclines, theN,N-dimethylglycylamido derivative of minocycline and 6-demethyl-6-deoxytetracycline, possesses activity against bacterial isolates containing the two major determinants responsible for tetracycline resistance: ribosomal protection and active efflux. The in vitro activities of TBG-MINO and the comparative agents were evaluated against strains with characterized tetracycline resistance as well as a spectrum of recent clinical aerobic and anaerobic gram-positive and gram-negative bacteria. TBG-MINO, with an MIC range of 0.25 to 0.5 μg/ml, showed good activity against strains expressing tet(M) (ribosomal protection), tet(A), tet(B),tet(C), tet(D), and tet(K) (efflux resistance determinants). TBG-MINO exhibited similar activity against methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant streptococci, and vancomycin-resistant enterococci (MICs at which 90% of strains are inhibited, ≤0.5 μg/ml). TBG-MINO exhibited activity against a wide diversity of gram-negative aerobic and anaerobic bacteria, most of which were less susceptible to tetracycline and minocycline. The in vivo protective effects of TBG-MINO were examined against acute lethal infections in mice caused by Escherichia coli, S. aureus, andStreptococcus pneumoniae isolates. TBG-MINO, administered intravenously, demonstrated efficacy against infections caused byS. aureus including MRSA strains and strains containingtet(K) or tet(M) resistance determinants (median effective doses [ED50s], 0.79 to 2.3 mg/kg of body weight). TBG-MINO demonstrated efficacy against infections caused by tetracycline-sensitive E. coli strains as well asE. coli strains containing either tet(M) or the efflux determinant tet(A), tet(B), ortet(C) (ED50s, 1.5 to 3.5 mg/kg). Overall, TBG-MINO shows antibacterial activity against a wide spectrum of gram-positive and gram-negative aerobic and anaerobic bacteria including strains resistant to other chemotherapeutic agents. The in vivo protective effects, especially against infections caused by resistant bacteria, corresponded with the in vitro activity of TBG-MINO.

scholarly journals Recovery of interfering and β-lactamase-producing bacteria from group A β-haemolytic streptococci carriers and non-carriers

2006 ◽  
Vol 55 (12) ◽  
pp. 1741-1744 ◽  
Author(s):  
Itzhak Brook ◽  
Alan E. Gober
Keyword(s):  
Anaerobic Bacteria ◽  
Healthy Children ◽  
Group A ◽  
Rate Of Recovery ◽  
Aerobic And Anaerobic

The purpose of this study was to compare the frequency of recovery of aerobic and anaerobic organisms with interfering capability against group A β-haemolytic streptococci (GABHS) and β-lactamase-producing bacteria (BLPB) from the tonsils of GABHS carriers and non-carriers. The presence of aerobic and anaerobic bacteria capable of such interference in vitro was evaluated in cultures obtained from the tonsils of 20 healthy children who were non-GABHS carriers and 20 who were GABHS carriers, and also from 20 children who were asymptomatic after completing a course of penicillin for acute GABHS pharyngo-tonsillitis (PT) and were non-GABHS carriers and 20 who were GABHS carriers. In healthy children, 32 interfering isolates were recovered from 16 non-GABHS carriers (1.6 per child) and 13 were isolated from 7 GABHS carriers (0.65 per child) (P<0.001). In children who had suffered acute GABHS PT, 26 interfering organisms were recovered from 15 non-GABHS carriers (1.3 per child) and 8 were isolated from 5 GABHS carriers (0.4 per child) (P<0.005). In healthy children, 13 BLPB were recovered from 5 non-GABHS carriers and 13 were isolated from 6 GABHS carriers. In children who had suffered acute GABHS PT, 14 BLPB were recovered from 5 (25 %) non-GABHS carriers and 32 were isolated from 17 (85 %) GABHS carriers (P<0.05). It was demonstrated in this study that there was a higher rate of recovery of aerobic and anaerobic organisms capable of interfering with GABHS in non-GABHS carriers than in GABHS carriers. This was observed in all GABHS non-carriers and included healthy children as well as those recently treated for symptomatic GABHS PT with penicillin that failed to eradicate GABHS. A higher rate of recovery of BLPB was observed only in GABHS carriers who were treated with penicillin for GABHS PT.

scholarly journals Bactericidal and Morphological Effects of NE-2001, a Novel Synthetic Agent Directed against Helicobacter pylori

2005 ◽  
Vol 49 (8) ◽  
pp. 3468-3473 ◽  
Author(s):  
Guofei Dai ◽  
Ni Cheng ◽  
Lei Dong ◽  
Mutsumi Muramatsu ◽  
Shudong Xiao ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Anaerobic Bacteria ◽  
Antibacterial Activities ◽  
Clinical Isolates ◽  
Synthetic Compound ◽  
Morphological Alterations ◽  
Transmission Electron Microcopy ◽  
Transmission Electron ◽  
Bactericidal Effects ◽  
Aerobic And Anaerobic

ABSTRACT The antibacterial activities of NE-2001 were tested against 24 clinical isolates of Helicobacter pylori and compared with those of amoxicillin, clarithromycin, metronidazole, and furazolidone. The MIC50 and MIC90 of this synthetic compound on the isolates were 8 and 16 μg/ml, respectively. This action was highly selective against Helicobacter pylori; there was a >4-fold difference between the concentration of NE-2001 required to inhibit the growth of Helicobacter pylori and that required to inhibit the growth of common aerobic and anaerobic bacteria. Exposure of Helicobacter pylori (ATCC43504) to NE-2001 at the MIC (4 μg/ml), or at a greater concentration, resulted in an extensive loss of viability. The phenomenon was also observed at pH levels between 3.0 and 7.0. When two clinical Helicobacter pylori strains were successively cultured at subinhibitory concentrations of NE-2001, no significant changes in the bactericidal effects were found. The morphological alterations of Helicobacter pylori cells (ATCC43504), exposed to NE-2001 at various concentrations for 6 h, were observed using transmission electron microcopy. The bacterium displayed features such as swelling, vacuole-like structures in the cytoplasm, and cell destruction following exposure to NE-2001. The efficacy of NE-2001 was maintained when evaluated in eight clinical isolates resistant to metronidazole and five isolates resistant to both metronidazole and clarithromycin (MIC ranging between 4 and 16 μg/ml). The above-described results suggest that NE-2001 may have the potential to be developed as a candidate agent for the treatment of Helicobacter pylori infection.

scholarly journals In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in Spain

2002 ◽  
Vol 46 (3) ◽  
pp. 892-895 ◽  
Author(s):  
Carmen Betriu ◽  
Iciar Rodríguez-Avial ◽  
Blas Ali Sánchez ◽  
María Gómez ◽  
Juan Álvarez ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Stenotrophomonas Maltophilia ◽  
Wide Spectrum ◽  
Anaerobic Bacteria ◽  
Antimicrobial Activities ◽  
Coagulase Negative Staphylococci ◽  
Medical Centers ◽  
Aerobic And Anaerobic

ABSTRACT The antimicrobial activities of tigecycline (GAR-936) were compared with those of other agents against 1,087 strains recently isolated in 12 Spanish medical centers. Tigecycline showed activity against a wide spectrum of aerobic and anaerobic bacteria, including strains such as methicillin-resistant Staphylococcus aureus, coagulase-negative staphylococci, penicillin-resistant Streptococcus pneumoniae, Enterococcus faecium, Acinetobacter baumannii, and Stenotrophomonas maltophilia.

Sign in / Sign up

Export Citation Format

Share Document